Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
Sponsor: Wake Forest University Health Sciences
Summary
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Official title: Evaluating the Use of Microarray Pharmacogenetic Testing in Patients With Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2025-07-18
Completion Date
2026-12
Last Updated
2026-02-02
Healthy Volunteers
No
Conditions
Interventions
Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
Pharmacogenomic (PGx) microarray testing will test for certain pharmcogenes that can guide prescribing of certain cancer treatments and/or supportive care medications.
Locations (1)
Atrium Health Levine Cancer
Charlotte, North Carolina, United States